Datasheet for ABIN390128

anti-AF9 antibody (C-Term)

2 Images | 2 Publications

Go to Product page

Overview

Quantity:	400 µL
Target:	AF9 (MLLT3)
Binding Specificity:	AA 471-502, C-Term
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This AF9 antibody is un-conjugated
Application:	Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details

Immunogen:	This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).
Clone:	RB2249-2250
Isotype:	Ig Fraction
Predicted Reactivity:	M
Purification:	This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Target Details

Target:	AF9 (MLLT3)

Target Details

Alternative Name:	AF9 (MLLT3) (MLLT3 Products)
Background:	The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.
Molecular Weight:	63351
Gene ID:	4300
NCBI Accession:	NP_004520
UniProt:	P42568

Application Details

Application Notes:	WB: 1:1000. IHC-P: 1:50~100
Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small

Handling

	aliquots to prevent freeze-thaw cycles.
Expiry Date:	6 months

Publications

Product cited in:

Benedikt, Baltruschat, Scholz, Bursen, Arrey, Meyer, Varagnolo, Müller, Karas, Dingermann, Marschalek: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." in: **Leukemia**, Vol. 25, Issue 1, pp. 135-44, (2011) (PubMed).

Bitoun, Oliver, Davies: "The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling." in: **Human molecular genetics**, Vol. 16, Issue 1, pp. 92-106, (2007) (PubMed).

Images



Immunohistochemistry (Paraffin-embedded Sections)

Image 1. Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry, clinical relevance has not been evaluated. BC = breast carcinoma, HC = hepatocarcinoma.



Western Blotting

Image 2. Western blot analysis of AF9 (MLLT3) Antibody (C-term) (ABIN390128 and ABIN2840633) in 293 cell line lysates (35 µg/lane). MLLT3(arrow) was detected using the purified Pab.